Comparative efficacy of multiple drugs for non-alcoholic fatty liver disease: a Bayesian network meta-analysis
Year: 2025
Type: article
Study designs: Systematic Review, Meta-Analysis
Abstract: BACKGROUND: Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is the most prevalent chronic liver disease worldwide. However, it remains unclear which drug treatment is more effective. Therefore, we conducted a network meta-analysis to comprehensively compare the efficacy of several potentially beneficial hypoglycemic drugs and vitamin E in treating patients with NAFLD. METHODS: This Bayesian network meta-analysis searched PubMed, Embase, Web of Science, and the Cochrane Library for randomized controlled trials (RCTs). We employed random-effects models to calculate mean differences (MD), relative risk (RR), and 95% confidence intervals (CI). The study outcomes included anthropometric measurements, biological markers, hepatic fat content, and liver biopsy results. The protocol for this systematic review with network meta-analysis was registered on PROSPERO (CRD42024532600). RESULTS: This analysis included 26 RCTs with 2143 patients. Based on the surface under the cumulative ranking curve and the network meta-analysis matrix, glucagon-like peptide-1 receptor agonists (GLP-1RA) demonstrated superior efficacy compared to other interventions, particularly in terms of weight loss, improvement in liver enzymes, resolution of non-alcoholic steatohepatitis (NASH), reduction of hepatic fat content, glycemic control, and improvement in insulin resistance. Additionally, compared to placebo, sodium-glucose cotransporter protein-2 inhibitors (SGLT-2I) showed moderate benefits in weight loss (body mass index: MD - 1.20, 95% CI - 1.83 to - 0.71; waist circumference: MD - 2.03, 95% CI - 3.32 to - 0.74) and reduction in liver enzyme levels (alanine aminotransferase: MD - 12.96, 95% CI - 19.24 to - 6.86; aspartate aminotransferase: MD - 9.53, 95% CI - 14.20 to - 5.06). Overall, thiazolidinediones (TZD) provided significant histological benefits; however, they also carried a risk of weight gain. Vitamin E was also found to improve liver enzyme levels and histological features. According to the GRADE framework assessment, most of these findings are supported by evidence of moderate certainty. CONCLUSIONS: The present study suggests that GLP-1RA may be the optimal treatment for NAFLD patients. In addition, current evidence does not sufficiently evaluate the impact of SGLT-2I on reducing liver fat content or histological outcomes. The potential risk of weight gain associated with TZD appears to be a limitation to their use. Vitamin E may be a suitable option for nondiabetic patients with NAFLD.
Authors: Zhile Xiao, Xiaonan Li, Jiahong Gong, Feng Zhou
Institution: Zhongnan Hospital of Wuhan University
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,190
Award: G612939834
OpenAlex ID: W4416594729